Orexin A Research: What Published Studies Have Investigated

What is orexin A?

What is orexin A? A 33-residue neuropeptide produced by a small population of neurons in and around the lateral and posterior hypothalamus. It is cut from a 131-residue precursor, prepro-orexin (UniProt O43612), which yields two mature peptides: orexin A from residues 34–66 and orexin B from residues 70–97. Both peptides act at the same two G-protein-coupled receptors, OX₁R and OX₂R.

It is also called hypocretin-1. The two names are not two compounds, and the duplication is not sloppiness — it is a historical artefact of the discovery, described below.

Discovery and origin in the literature

This section is the shared history of both peptides, and it is written once, here. The orexin B page refers back to it rather than restating it.

January 1998: the hypocretins

De Lecea and colleagues reported in PNAS on 6 January 1998 (PMID 9419374) a hypothalamus-specific mRNA encoding a precursor they called preprohypocretin, yielding a pair of peptides sharing substantial amino-acid identity with the gut hormone secretin. They localised the protein products to neuronal cell bodies in the dorsal and lateral hypothalamic areas, traced widespread projections to the brainstem and thalamus, found the immunoreactivity associated with large granular vesicles at synapses, and reported that one of the peptides was excitatory when applied to cultured hypothalamic neurons but not to hippocampal neurons. Their conclusion was that these were neurotransmitters. The name combines hypothalamus and secretin.

February 1998: the orexins

Six weeks later, Sakurai and colleagues reported in Cell (PMID 9491897) two novel neuropeptides from the same precursor that bound and activated two closely related, previously orphan G-protein-coupled receptors. Their route was the opposite one: they had the orphan receptors and went looking for the ligands. They reported that prepro-orexin mRNA and orexin-A immunoreactivity localise to neurons in and around the lateral and posterior hypothalamus, that central administration stimulated food consumption in rats, and that prepro-orexin mRNA was upregulated on fasting. The name comes from orexis, appetite.

Both names stuck, and both remain in the literature — usually with the sleep field preferring hypocretin and the receptor-pharmacology field preferring orexin. A reader searching this literature should search both terms; a substantial fraction of the corpus is invisible under either one alone.

1999–2000: the field changes subject

Feeding was the initial framing and it did not stay the main one. Chemelli and colleagues reported in Cell in 1999 (PMID 10481909) that orexin-knockout mice displayed a narcolepsy phenotype, and Lin and colleagues reported the same year that canine narcolepsy is caused by a mutation in the receptor gene — a result that belongs to the orexin B page, because the receptor involved is OX₂R. Within two years the human work below had recast the entire system as a wakefulness circuit whose failure produces narcolepsy.

Reference data

From the reviewed UniProt record for the human precursor (O43612) and the public chemical record (PubChem CID 56842143).

Three of those rows do most of the work in distinguishing this peptide from its sibling: the four cysteines (hence the four sulfur atoms in the formula), the pyroglutamate terminus, and the resulting mass of roughly 3561 Da against orexin B’s roughly 2899 Da. No reconstitution procedure, quantity or route is given or implied on this page.

Mechanisms researchers have examined

• Non-selective receptor activation. Orexin A is described throughout this literature as the non-selective ligand of the pair, activating both OX₁R and OX₂R. The IUPHAR/BPS Guide to Pharmacology lists it as an agonist at both, with published potency ranges at each receptor that overlap heavily. The ranges themselves are wide across studies, which is worth registering: assay format, cell background and readout all move these numbers, and single quoted figures from secondary sources should be treated with caution.
• Structural basis of the difference from orexin B. Kim and colleagues (2004, J Biochem Mol Biol, PMID 15479620) determined the solution structure of orexin A by NMR and simulated annealing, reporting two alpha-helices with hydrophobic residues on one face and hydrophilic on the other, and identifying a hydrophilic turn induced by the two disulfide bonds as the key structural difference between orexin A and orexin B.
• Neuronal excitation. De Lecea et al. (1998) reported that a hypocretin peptide excited cultured, synaptically coupled hypothalamic neurons but not hippocampal neurons — an early indication that the system’s targets are anatomically specific rather than general.
• Feeding circuitry. Sakurai et al. (1998) reported that central administration in rats stimulated food consumption and that precursor mRNA rose on fasting. This was the original framing and remains a genuine finding; it is no longer the dominant one.

Research findings by area

The narcolepsy result, and why orexin A is the analyte

This is the part of the literature that belongs to orexin A specifically, and it is unusually strong for a peptide of this kind — three independent lines converging in a single year.

• Cerebrospinal fluid. Nishino and colleagues reported in the Lancet in January 2000 (PMID 10615891) hypocretin deficiency in human narcolepsy, measuring hypocretin-1 — orexin A — in CSF. That choice of analyte is why this page carries the clinical strand and the orexin B page does not.
• Post-mortem peptide. Peyron and colleagues reported in Nature Medicine in September 2000 (PMID 10973318) a generalised absence of hypocretin peptides in human narcoleptic brains, together with a mutation identified in one early-onset case.
• Post-mortem cell counts. Thannickal and colleagues reported in Neuron the same month (PMID 11055430) a reduced number of hypocretin neurons in human narcolepsy — the anatomical counterpart of the biochemical finding.

Taken with the 1999 mouse and dog genetics, this is a rare case of a neuropeptide system whose loss-of-function phenotype was established in three species by three methods in about eighteen months. It is the strongest evidence base of any compound covered on this page’s cluster.

What was built on it

The therapeutic output of this system to date has been small-molecule antagonists of the receptors rather than the peptide itself — the dual orexin receptor antagonists used in insomnia, of which suvorexant was the first approved. That direction matters for reading the literature: the enormous body of work on orexin pharmacology since 2010 is largely about blocking these receptors, and results from that work do not transfer to statements about the peptide.

Research models and evidence status

Where the evidence is genuinely strong

The existence, structure, precursor and anatomical distribution of orexin A are settled facts with a reviewed protein-database record behind them. Its receptor pharmacology is characterised across many laboratories and aggregated by an independent curation project. Its association with narcolepsy is one of the better-replicated findings in sleep neuroscience. None of that is in doubt, and this page does not hedge it.

What is not established

What is not established is anything about administering the peptide. There is no published human pharmacokinetic, safety or tolerability dataset for orexin A as an administered compound that we could locate. The clinical evidence base in this system is about measuring the peptide as a biomarker and about blocking its receptors with small molecules; neither of those is evidence about giving the peptide to anyone.

The peptide’s structure also makes it an awkward research reagent, and honesty requires saying so. Two intrachain disulfide bonds mean the molecule’s activity depends on correct disulfide pairing, which synthesis must achieve and which a purity percentage does not report; a mis-paired isomer has the same mass and may co-elute. That is an analytical limitation, discussed below, and it applies to this peptide far more than to its linear sibling.

Nothing in this literature establishes any property of the supplied research material in a person. This page makes no efficacy, therapeutic, wakefulness, appetite or other use claim of any kind, and the material is supplied for laboratory research use only — not for human or veterinary use.

How to verify this compound yourself

Orexin A is one of the harder peptides in this catalogue to certify properly, and the reason is structural:

• Mass-spec identity separates it cleanly from orexin B. Roughly 3561 Da against roughly 2899 Da is an enormous, unmistakable difference. If a certificate reports a mass in the wrong range for the peptide named on the label, nothing else on the document matters.
• Disulfide pairing is the hidden variable. Four cysteines can be joined in three different pairings, only one of which is the native arrangement. All three have the same molecular formula and the same mass. A routine COA reporting HPLC purity and a molecular ion cannot distinguish correctly folded orexin A from a mis-paired isomer. Establishing the pairing requires peptide mapping — enzymatic digestion followed by MS of the resulting disulfide-linked fragments — and that is a specialist analysis, not a standard line item.
• Free-thiol content is the practical proxy. An Ellman-type free-thiol assay indicates whether cysteines remain unoxidised. It does not prove correct pairing, but a material with significant free thiol is definitively not fully oxidised, and that is worth knowing.
• The pyroglutamate terminus is a real synthesis variable — an unconverted N-terminal glutamine differs in mass from pyroglutamate by 17 Da, which mass spectrometry resolves easily if anyone looks.
• HPLC purity on a 33-residue peptide is a meaningful figure. At this length deletion sequences accumulate, so the percentage carries genuine information — unlike on a tripeptide, where a high number is nearly automatic.

See how to read a COA for what each certificate line means, and how to verify peptide purity for how the methods fit together and where they stop. The exact batch received can be checked on the self-serve verify tool.

Research-grade sourcing and verification

Orexin A is not held in stock. It is listed on our sourcing catalogue as available to order — our supplier lists it, we have not bought it, and material of this kind typically takes about two to three weeks to reach us. For laboratory research use only, it is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation, verifiable at the lot level — with the disulfide-pairing limitation above stated rather than glossed. Its sibling peptide has its own page: orexin B research. For other endogenous peptides in this library studied in sleep and circadian contexts, see DSIP research and melatonin research. This is sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. de Lecea L, Kilduff TS, Peyron C, et al. “The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.” Proc Natl Acad Sci U S A. 1998;95(1):322–327. PMID 9419374. pubmed.ncbi.nlm.nih.gov/9419374. The hypocretin naming.
2. Sakurai T, Amemiya A, Ishii M, et al. “Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.” Cell. 1998;92(4):573–585. PMID 9491897. pubmed.ncbi.nlm.nih.gov/9491897. The orexin naming and the receptor deorphanisation.
3. Chemelli RM, Willie JT, Sinton CM, et al. “Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.” Cell. 1999;98(4):437–451. PMID 10481909. pubmed.ncbi.nlm.nih.gov/10481909.
4. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. “Hypocretin (orexin) deficiency in human narcolepsy.” Lancet. 2000;355(9197):39–40. PMID 10615891. pubmed.ncbi.nlm.nih.gov/10615891. The CSF measurement.
5. Peyron C, Faraco J, Rogers W, et al. “A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.” Nat Med. 2000;6(9):991–997. PMID 10973318. pubmed.ncbi.nlm.nih.gov/10973318.
6. Thannickal TC, Moore RY, Nienhuis R, et al. “Reduced number of hypocretin neurons in human narcolepsy.” Neuron. 2000;27(3):469–474. PMID 11055430. pubmed.ncbi.nlm.nih.gov/11055430.
7. Kim HY, Hong E, Kim JI, Lee W. “Solution structure of human orexin-A: regulator of appetite and wakefulness.” J Biochem Mol Biol. 2004;37(5):565–573. PMID 15479620. pubmed.ncbi.nlm.nih.gov/15479620. Source of the disulfide-turn structural difference.
8. UniProt Consortium. “O43612 — Hypocretin neuropeptide precursor (human).” uniprot.org/uniprotkb/O43612 (precursor length, peptide boundaries, terminal modifications, disulfide bonds).
9. National Center for Biotechnology Information. “PubChem Compound Summary for CID 56842143, Orexin A.” pubchem.ncbi.nlm.nih.gov/compound/56842143 (formula, mass, CAS 205599-75-3).
10. Harding SD, Armstrong JF, Faccenda E, et al. “OX₁ and OX₂ receptors.” IUPHAR/BPS Guide to Pharmacology. guidetopharmacology.org (curated agonist potency ranges for orexin A and orexin B at both receptors).